Lupin shuts down Indian plant after 18 workers test positive for COVID-19: report

India's pharmaceutical manufacturing is no stranger to the novel coronavirus after multiple waves of infections have temporarily shut down operations at a number of drugmakers' sites. Now, a Lupin site that produces generic asthma and diabetes meds to the U.S. is going into lockdown.